Lenacapavir Tablet
Sponsors
Gilead Sciences
Conditions
HIV InfectionsHIV Pre-exposure ProphylaxisHIV-1 InfectionHIV-1-infectionPre-Exposure Prophylaxis of HIV Infection
Phase 2
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Active, not recruitingNCT05729568
Start: 2023-05-15End: 2030-12-01Updated: 2026-04-27
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Active, not recruitingNCT06101342
Start: 2023-12-13End: 2028-01-01Updated: 2026-03-02
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Active, not recruitingNCT06101329
Start: 2023-11-17End: 2028-01-31Updated: 2025-09-23
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Active, not recruitingNCT06513312
Start: 2024-10-07End: 2028-11-01Updated: 2026-06-15
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
RecruitingNCT07645287
Start: 2026-06-15End: 2033-04-01Target: 175Updated: 2026-07-10
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
Not yet recruitingNCT07708727
Start: 2026-07-01End: 2033-04-01Target: 700Updated: 2026-07-16
Phase 3
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
Active, not recruitingNCT07047716
Start: 2025-07-22End: 2028-09-01Updated: 2026-06-22
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Not yet recruitingNCT07682961
Start: 2026-07-01End: 2033-03-01Target: 590Updated: 2026-07-06
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
Not yet recruitingNCT07683000
Start: 2026-07-01End: 2033-03-01Target: 590Updated: 2026-07-06